KRTL Holding Group Signs RAYEL Cooperation Agreement with Centro de Investigaciones Químicas S.R.L.

About this update from Krtl Holding Group, Inc

KRTL Holding Group Inc. (OTC: KRTL) (“KRTL” or the “Company”) today announced that its subsidiary, KRTL International Corp., has executed a strategic cooperation agreement with Centro de Investigaciones Químicas S.R.L. (“CIQ”) of Bolivia, represented by Dr. Marcelo Bascope, establishing a formal framework for continued scientific cooperation, documentation development, partner engagement, regulatory-planning review and preparation for future definitive agreements relating to the RAYEL coca-derived extract platform. KRTL views the agreement as an important shareholder update because it advances the RAYEL platform from prior planning and initial platform-development activities into a more structured working relationship with CIQ. The Company believes this step further aligns KRTL and CIQ around technical documentation, scientific contributions, partner-development initiatives, regulatory planning, commercialization preparation and the disciplined negotiation of future definitive agreements. “Reaching this agreement with CIQ and Dr. Bascope is an important step forward for KRTL and for the RAYEL platform,” said Cesar Herrera, Chief Executive Officer of KRTL Holding Group Inc. “We want to thank Dr. Bascope and CIQ for their trust, collaboration and continued support. We recognize and respect the scientific, technical, formulation, extraction-methodology, laboratory, documentation and development expertise that CIQ has contributed to RAYEL.” Mr. Herrera continued, “This agreement provides both organizations with a clearer framework to continue working together as RAYEL enters a more structured phase of development. It reflects the relationship we have built, the work already completed and our shared commitment to advancing RAYEL through careful documentation, scientific review, technical validation and responsible commercial planning.” “Clear communication and responsible disclosure are important to how we operate,” Mr. Herrera added. “As we prepare RAYEL for future partner discussions, regulatory review, financing discussions, manufacturing evaluation and definitive agreements, we believe continued coordination between KRTL and CIQ will be essential.” Under the agreement, KRTL and CIQ intend to coordinate on RAYEL documentation, CIQ-approved data-room materials, scientific and technical review, Bolivia-based research and technical cooperation, partner diligence, potential U.S. manufacturing and commercialization discussions, regulatory-planning review and preparation of future definitive agreements. The parties also intend to coordinate documentation relating to scientific know-how, formulation records, extraction methodologies, laboratory materials, supporting research and other technical information that may be relevant to future manufacturing, licensing, investment, regulatory or commercial discussions. The agreement recognizes a shared commercial framework for potential RAYEL opportunities. Final economics, ownership rights, implementation terms, commercialization structures, licensing arrangements and other material transaction terms remain subject to negotiation and execution of future definitive written agreements. KRTL has begun preliminary partner-development and commercialization-planning efforts for RAYEL, including introductions through existing industry relationships to prospective U.S. manufacturing and strategic partners. These discussions are exploratory and are intended to evaluate possible manufacturing, licensing, commercialization, distribution, regulatory-planning, funding and strategic-partnership pathways as the project continues to mature. For KRTL, the agreement represents a meaningful step toward building a documentation-driven and partner-oriented platform for the responsible development of a regulated international extract opportunity. The Company believes that clear documentation, scientific cooperation, technical review, partner diligence and regulatory planning are important to supporting long-term project credibility and shareholder value. The cooperation agreement is not a licensing, manufacturing, distribution, purchase, financing or commercialization agreement. It does not establish final economics and does not authorize any regulated activity. RAYEL remains subject to documentation, scientific and technical validation, legal and regulatory review, partner diligence, financing, definitive written agreements and applicable approvals. The agreement does not authorize the import, export, manufacture, handling, processing, storage, distribution, commercialization, transfer or use of any controlled substance, coca-derived material, alkaloid, active pharmaceutical ingredient, pharmaceutical material, regulated product, restricted technical material, or whole-plant or whole-extract material. Any such activity may occur only through properly authorized entities and under all required registrations, licenses, quotas, permits, governmental authorizations, regulatory approvals, compliance procedures and definitive written agreements. The Company intends to provide additional shareholder updates as appropriate, subject to confidentiality obligations, partner approvals, regulatory limitations and applicable disclosure requirements. About KRTL Holding Group Inc. KRTL Holding Group Inc. (OTC: KRTL) is a diversified holding company pursuing biotechnology, technology, international development and subsidiary-led project opportunities. Through its subsidiaries and affiliated project structures, KRTL works to develop, coordinate and commercialize opportunities in regulated and emerging-growth sectors. About KRTL International Corp. KRTL International Corp. is a subsidiary of KRTL Holding Group Inc. focused on international project development, strategic partnerships, documentation-driven project coordination and regulated-opportunity development. About Centro de Investigaciones Químicas S.R.L. Centro de Investigaciones Químicas S.R.L. (“CIQ”) is a Bolivian private scientific institute with capabilities in pharmaceutical development, analytical chemistry, food chemistry, environmental testing, agricultural research and compound analysis. CIQ’s role in RAYEL is subject to the cooperation agreement and any future definitive agreements. Forward-Looking Statements This press release contains forward-looking statements, including statements regarding RAYEL, PERIKO, scientific cooperation, documentation review, technical validation, partner discussions, manufacturing evaluation, commercialization planning, regulatory-planning pathways, data-room development, future definitive agreements, potential licensing, potential commercialization, potential pharmaceutical or API-oriented development, potential funding pathways and future business opportunities. Forward-looking statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially. No assurance can be given that any documentation review, partner discussion, manufacturing arrangement, financing, regulatory approval, commercialization agreement, licensing agreement, distribution agreement, pharmaceutical or API-oriented pathway, or revenue-generating activity will be completed. RAYEL and related activities remain subject to legal, regulatory, scientific, technical, quality, safety, import and export, controlled-substance, pharmaceutical, food and beverage, labeling, manufacturing, partner-diligence, financing and market-readiness review. Forward-looking statements speak only as of the date of this release, and KRTL undertakes no obligation to update them except as required by applicable law.

View stock analysis, news, and events for Krtl Holding Group, Inc